Andrew Brake
Nurse Practitioner · Greensboro, NCNPI 1174022743
Payments from drug & device makers
Across 132 payments — averaging $17.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$394
- Novo Nordisk$318
- AstraZeneca$202
- Pfizer$197
- AbbVie$176
- Abbott$119
- plus $873 from 20 others
What the payments were for
- Food & beverage$2,279100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 24 | $394 |
| Novo Nordisk | 21 | $318 |
| AstraZeneca | 9 | $202 |
| Pfizer | 14 | $197 |
| AbbVie | 12 | $176 |
| Abbott | 6 | $119 |
| Amgen | 6 | $91 |
| Biohaven Pharmaceuticals, Inc. | 4 | $82 |
| GSK | 4 | $80 |
| Gilead | 3 | $77 |
| Boehringer Ingelheim | 5 | $76 |
| Irhythm Technologies, Inc. | 1 | $60 |
| Merck | 4 | $59 |
| Nevro Corp. | 2 | $58 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $41 |
| Esperion Therapeutics, Inc. | 2 | $40 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| Exact Sciences | 2 | $37 |
| Dexcom, Inc. | 1 | $25 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Bayer | 1 | $16 |
| Shield Therapeutics Inc | 1 | $16 |
| Inspire Medical Systems, Inc. | 1 | $14 |
| Ossur Americas, Inc. | 1 | $11 |
How this compares
$2,279 in reported general payments places this provider in the 85th percentile of 4,393 nurse practitioner providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 78 | $65,700 |
| JardianceEmpagliflozin | 45 | $59,044 |
| RybelsusSemaglutide | 20 | $46,911 |
| OzempicSemaglutide | 28 | $29,770 |
| TrulicityDulaglutide | 13 | $22,842 |
| JanuviaSitagliptin Phosphate | 17 | $21,592 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $17,587 |
| XareltoRivaroxaban | 11 | $11,227 |
| MyrbetriqMirabegron | 16 | $10,793 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $9,289 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 29 | $6,572 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $5,698 |
| Atorvastatin Calcium | 607 | $5,629 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $5,523 |
| PaxlovidNirmatrelvir/Ritonavir | 15 | $4,167 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $318 | $76,68148 claims |
| PfizerEliquis, Paxlovid | $197 | $69,86793 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $76 | $64,56857 claims |
| GSKTrelegy Ellipta, Shingrix | $80 | $24,15946 claims |
| Lilly USA, LLCTrulicity | $394 | $22,84213 claims |
| MerckJanuvia | $59 | $21,59217 claims |
| AstraZenecaSymbicort | $202 | $9,28925 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,393 nurse practitioner providers in North Carolina.
Other nurse practitioner in Greensboro
- Amber SeilerGreensboro$55K
- Dawn DrazekGreensboro$18K
- Mary PrevostGreensboro$12K
- Sandrivette JohnsonRaleigh$573K
- Skyler RogersPinehurst$174K
- Jamie DinerDurham$170K
- Ayeshia WrightMocksville$145K
- Deborah AllenDurham$112K
- Jeanann VawterGastonia$97K
- Terra KampJacksonville$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.